Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Other Non-Current Assets (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed Other Non-Current Assets for 7 consecutive years, with $3.6 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets fell 64.88% to $3.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.6 million through Dec 2025, down 64.88% year-over-year, with the annual reading at $3.6 million for FY2025, 64.88% down from the prior year.
  • Other Non-Current Assets hit $3.6 million in Q4 2025 for Allogene Therapeutics, up from $3.5 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $10.3 million in Q1 2022 to a low of $3.5 million in Q3 2025.
  • Historically, Other Non-Current Assets has averaged $8.4 million across 5 years, with a median of $9.4 million in 2021.
  • Biggest five-year swings in Other Non-Current Assets: surged 337.45% in 2021 and later tumbled 65.87% in 2025.
  • Year by year, Other Non-Current Assets stood at $5.8 million in 2021, then skyrocketed by 76.99% to $10.3 million in 2022, then plummeted by 35.83% to $6.6 million in 2023, then soared by 55.84% to $10.3 million in 2024, then crashed by 64.88% to $3.6 million in 2025.
  • Business Quant data shows Other Non-Current Assets for ALLO at $3.6 million in Q4 2025, $3.5 million in Q3 2025, and $3.8 million in Q2 2025.